ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1365

Incidence Of Hepatitis B Virus Reactivation In Patients With Rheumatoid Arthritis During Treatment With Biologics

Jun Nakamura1, Takao Nagashima1, Katsuya Nagatani2, Taku Yoshio3, Masahiro Iwamoto4 and Seiji Minota5, 1Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, 2Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, 3Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, 4Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Tochigi, Japan, 5The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologics, Hepatitis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose: Reactivation of hepatitis B virus (HBV) is very problematic in patients who are receiving biologics. Optimal precaution and management for those patients are still controversial. The aim of this study is to clarify the incidence of HBV reactivation in rheumatoid arthritis (RA) patients on biologics and to find out whether there is difference in reactivation rates among different biologics.

Methods: Retrospective observational study. HBV reactivation was defined as conversion from quantitative negativity to qualitative positivity of HBV-DNA in sera. All the patients with RA who were treated with biologics from July 2010 to December 2012 were tested for HBsAg, anti-HBs and anti-HBc. If the patients were positive for HBsAg, or negative for HBsAg but positive for anti-HBs and/or anti-HBc, ALT and AST were also retrieved from patients’ records. HBsAg, anti-HBs and anti-HBc were examined using chemiluminescent immunoassay, and the levels of HBV-DNA were measured by real-time PCR (lowest detection limit was 2.1 log copies/ml). The ethics committee of our hospital approved this study.

Results: Among 247 patients received biologics, none was found positive for HBsAg. 57 patients (23.0%) were negative for HBsAg but positive for anti-HBs and/or anti-HBc. These patients were considered to have resolved HBV infection. Infliximab, etanarcept, adalimumab, tocilizumab and abatacept were used in 27, 25, 17, 18 and one, respectively; some of the patients received multiple biologics. HBV-DNA became positive in 4 patients (7.0%): 1 while on etanercept, 1 while on infliximab, and 2 while on tocilizumab. However, the levels of HBV-DNA were below the quantitative detection limits in these 4 patients. In one patient on tocilizumab, HBV-DNA levels fluctuated between positive and negative ranges for 4 months; first HBV-DNA positivity was found at 2 months after tocilizumab-use. In another case on tocilizumab, HBV-DNA was first found at 2 months after tocilizumab-use, persisted for 3 months, and disappeared thereafter. In one patient on infliximab, HBV-DNA became positive only once at 22 months after infliximab-use. In one patient on etanercept, HBV-DNA was found only once at 17 months after etanercept-use. Liver function tests were within normal ranges in all examinations from all the patients. All the patients continued treatment with the biologics and HBV-DNA became negative eventually without anti-viral treatment.

Conclusion: HBV reactivation was observed in 7.0% of RA patients with resolved HBV infection during treatment with biologics. However, HBV-DNA levels were below the quantitative detection limits and liver function tests were normal throughout. There were no differences among biologics in regards to the incidence of HBV reactivation. Anti-TNFs and anti-IL-6 receptor antibody may be used safely in RA patients with a history of HBV infection.


Disclosure:

J. Nakamura,
None;

T. Nagashima,
None;

K. Nagatani,
None;

T. Yoshio,
None;

M. Iwamoto,
None;

S. Minota,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-hepatitis-b-virus-reactivation-in-patients-with-rheumatoid-arthritis-during-treatment-with-biologics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology